CLPT on Nasdaq

ClearPoint Neuro, Inc.

We are a commercial-stage medical device company, incorporated in 1998 as a Delaware corporation, that develops and commercializes integrated systems used in minimally invasive neurosurgical.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Cytosorbents, RETRACTABLE TECHNOLOGIES INC or UTAH MEDICAL PRODUCTS INC, or pick any stock.

  • TickerCLPT on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersSolana Beach, California1
  • Incorporated inDE2
  • Business address120 S. Sierra Avenue, Suite 100, Solana Beach, Ca 920752
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a commercial-stage medical device company, incorporated in 1998 as a Delaware corporation, that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. From our inception in 1998, we have deployed significant resources to fund our efforts to develop the foundational capabilities for enabling magnetic resonance imaging (“MRI”) guided interventions, building an intellectual property portfolio, and identifying and building out commercial applications for the technologies we develop. In 2021, our efforts expanded beyond the MRI suite to encompass development and commercialization of neurosurgical device products for the operating room setting, as well as consulting services for pharmaceutical companies.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

61.4%Gross margin4
-65.4%Operating margin4
-69.1%Net margin4
17.8%Revenue growth, 20254
-91.1%Return on equity4
1.75×Debt to equity4
-$24.4MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Biologics And Drug Delivery - Services And License Fees brought in 43% of the revenue ClearPoint Neuro, Inc. broke down this way in fiscal 2025.

  1. Biologics And Drug Delivery - Services And License Fees$11.7M443%down 0% from 2024
  2. Biologics and Drug Delivery - Disposable Products$7.3M427%up 31% from 2024
  3. Capital Equipment and Software Revenue$3.1M411%down 18% from 2024
  4. Capital Equipment and Software-Related Service$2.1M48%down 9% from 2024
  5. Capital Equipment and Software - Systems and Software Products$1.7M46%down 38% from 2024
  6. Capital Equipment and Software - Services$1.4M45%up 33% from 2024
Products and services by year
Products and services20242025
Biologics And Drug Delivery - Services And License Fees$11.7M$11.7M
Biologics and Drug Delivery - Disposable Products$5.6M$7.3M
Capital Equipment and Software Revenue$3.8M$3.1M
Capital Equipment and Software-Related Service$2.3M$2.1M
Capital Equipment and Software - Systems and Software Products$2.7M$1.7M
Capital Equipment and Software - Services$1.1M$1.4M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue32¢$14.3M
  • Research and development31¢$13.9M
  • Selling, general and admin37¢$16.5M
  • Income tax0¢$55.0K

Out of $37.0M in revenue.4 The company lost money this year.

Financial statements

Revenue6789104$37.0M in 2025+230% since 2019
0$10.0M$20.0M$30.0M$40.0M2019: $11.2M$11.2M20192020: $12.8M$12.8M2020+14%2021: $16.3M$16.3M2021+27%2022: $20.6M$20.6M2022+26%2023: $24.0M$24.0M2023+17%2024: $31.4M$31.4M2024+31%2025: $37.0M$37.0M2025+18%
Gross profit789104$22.7M in 2025+149% since 2020
0$10.0M$20.0M$30.0M2020: $9.1M$9.1M20202021: $11.1M$11.1M2021+22%2022: $13.5M$13.5M2022+22%2023: $13.6M$13.6M2023+1%2024: $19.1M$19.1M2024+40%2025: $22.7M$22.7M2025+19%
Operating income6789104-$24.2M in 2025+426% since 2019
-$30.0M-$20.0M-$10.0M02019: -$4.6M-$4.6M20192020: -$6.2M-$6.2M2020+35%2021: -$13.4M-$13.4M2021+115%2022: -$16.3M-$16.3M2022+22%2023: -$22.4M-$22.4M2023+37%2024: -$19.7M-$19.7M2024−12%2025: -$24.2M-$24.2M2025+22%
Net income6789104-$25.5M in 2025+361% since 2019
-$30.0M-$20.0M-$10.0M02019: -$5.5M-$5.5M20192020: -$6.8M-$6.8M2020+22%2021: -$14.4M-$14.4M2021+112%2022: -$16.4M-$16.4M2022+14%2023: -$22.1M-$22.1M2023+34%2024: -$18.9M-$18.9M2024−14%2025: -$25.5M-$25.5M2025+35%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Total revenue$37.0M$31.4M
Cost of revenue$14.3M$12.3M
Gross profit$22.7M$19.1M
Research and development costs$13.9M$12.4M
Sales and marketing expenses$16.5M$14.5M
General and administrative expenses$16.5M$12.0M
Operating loss-$24.2M-$19.7M
Other expense, net-$146.0K-$40.0K
Interest income$1.2M$1.4M
Interest expense-$2.4M-$518.0K
Net loss before income taxes-$25.5M-$18.9M
Income tax expense$55.0K$12.0K
Net loss-$25.5M-$18.9M
Basic (in dollars per share)-$0.90-$0.70
Diluted (in dollars per share)-$0.90-$0.70
Basic (in shares)28.3M shares27.0M shares
Diluted (in shares)28.3M shares27.0M shares

Compare ClearPoint Neuro, Inc. with another company

Leadership

Who has led ClearPoint Neuro, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kimble L. Jenkins2012–2013
  2. Francis P. Grillo2015–2017
  3. Joseph Michael Burnett2017–now

Chair

  1. Kimble L. Jenkins2012

President

  1. Francis P. Grillo2014
  2. Joseph Michael Burnett2017–now

Chief financial officer

  1. Harold A. Hurwitz2015–2020
  2. Danilo D'Alessandro2021–now

Chief operating officer

  1. Peter G. Piferi2012–2021
  2. Mazin Sabra2022–now
201520202025
Board members and other officers (25)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorMatthew B. Klein named Feb 5, 202644

Former names

  • MRI INTERVENTIONS, INC.Jul 15, 2011 to Feb 11, 20202
  • SURGIVISION INCNov 6, 2009 to Oct 22, 20102
  • SURGI VISION INCMar 30, 2004 to May 2, 20072

Timeline

  1. Nov 7, 2017New chief executive Joseph Michael Burnett becomes CEO13
  2. Aug 17, 2015New chief executive Francis P. Grillo becomes CEO14
  3. Feb 27, 2012New chief executive Kimble L. Jenkins becomes CEO15

Filings

395 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 51 major events, 254 insider forms, 24 large holders, 1 private raises, 45 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Oct 2, 20264 EDGAR
  3. Sep 3, 20264 EDGAR
  4. Aug 12, 2026SCHEDULE 13G/A EDGAR
  5. Aug 4, 2026SCHEDULE 13G/A EDGAR
  6. Aug 3, 202610-Q EDGAR
  7. Aug 3, 20268-K EDGAR
  8. Jul 27, 2026SCHEDULE 13G/A EDGAR
  9. Jul 6, 20264 EDGAR
  10. Jul 6, 20264 EDGAR
  11. Jul 2, 20264 EDGAR
  12. Jul 2, 20264 EDGAR
  13. Jul 2, 20264 EDGAR
  14. Jul 1, 20264 EDGAR
  15. Jun 29, 2026144 EDGAR
  16. Jun 22, 20264 EDGAR
  17. Jun 17, 2026144 EDGAR
  18. Jun 17, 2026144 EDGAR
  19. Jun 8, 20264 EDGAR
  20. Jun 2, 20264 EDGAR

The 395 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

14 open-market trades by officers, directors and large owners since October 2021: 0 buys and 14 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 29, 2026BURNETT JOSEPHCEO and PresidentSale20,000$19.38$387.6KForm 4
Jun 17, 2026BURNETT JOSEPHCEO and PresidentSale61,843$17.79$1.1MForm 4
Jun 1, 2026Richards Timothy T.DirectorSale5,415$12.17$65.9KForm 4
May 21, 2026Klein Matthew B.DirectorSale16,000$11.59$185.4KForm 4
May 20, 2026FALLON LYNNETTE CDirectorSale5,091$11.14$56.7KForm 4
Feb 25, 2026BURNETT JOSEPHCEO and PresidentSale19,951$15.17$302.7KForm 4
Jan 26, 2026BURNETT JOSEPHCEO and PresidentSale2,943$15.57$45.8KForm 4
Jan 9, 2026BURNETT JOSEPHCEO and PresidentSale20,000$16.12$322.4KForm 4
Oct 10, 2025BURNETT JOSEPHCEO and PresidentSale26,463$26.98$714.0KForm 4
Jun 10, 2025Richards Timothy T.DirectorSale10,000$13.28$132.8KForm 4
Jun 9, 2025BURNETT JOSEPHCEO and PresidentSale21,247$13.29$282.4KForm 4
Jun 3, 2025FALLON LYNNETTE CDirectorSale10,200$12.57$128.2KForm 4
Aug 15, 2022BURNETT JOSEPH MICHAELCEO and PresidentSale18,867$16.07$303.2KForm 4
Nov 11, 2021BURNETT JOSEPH MICHAELCEO and PresidentSale10,000$16.88$168.8KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 20, 2025Raised $17.9 million in a private offering of equity Form D: 46 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.2,379,804$42.5M0.0%+297,054
Mak Capital One LLC2,375,861$42.4M5.9%+474,372
Vanguard Capital Management LLC1,232,807$22.0M0.0%−10,808
State Street Corp816,547$14.6M0.0%+136,728
Geode Capital Management, LLC749,932$13.4M0.0%+44,212
Lane Generational LLC444,831$7.9M7.0%−42,018
UBS Group AG428,632$7.6M0.0%−3,728
Millennium Management LLC357,676$6.4M0.0%+125,702
Brown Advisory Inc325,906$5.8M0.0%No change
Compass Financial Management LLC295,680$5.3M0.6%New
Susquehanna International Group, Llp240,282$4.3M0.0%+103,998
Northern Trust Corp230,986$4.1M0.0%+21,560
Pier Capital, LLC222,761$4.0M0.5%New
Vanguard Fiduciary Trust Co213,246$3.8M0.0%+7,491
Vanguard Portfolio Management LLC194,584$3.5M0.0%−90,225
Tudor Investment Corp Et Al173,759$3.1M0.0%+16,788
Morgan Stanley165,786$3.0M0.0%+35,914
Two Sigma Investments, LP154,851$2.8M0.0%−55,929
Bank of New York Mellon Corp151,767$2.7M0.0%+8,020
Parsons Capital Management Inc/ri148,976$2.7M0.1%−194
Pekin Hardy Strauss, Inc.143,375$2.6M0.2%+3,000
Goldman Sachs Group Inc138,911$2.5M0.0%−324,706
Taylor Frigon Capital Management LLC132,009$2.4M1.1%+108
CM Management, LLC125,000$2.2M1.4%−25,000
Diametric Capital, LP123,293$2.2M0.2%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50